SOURCE: Velcera, Inc.

November 02, 2007 06:00 ET

Velcera Shares Commence Trading on OTC-Bulletin Board

YARDLEY, PA--(Marketwire - November 2, 2007) - Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today that the shares of its common stock have commenced trading under ticker symbol "VLCR.OB" on the over-the-counter bulletin board.

"The trading of Velcera shares provides investors with a new investment opportunity within the expanding pet health segment," stated Dennis Steadman, President and CEO of Velcera, Inc. "We are excited to have reached this milestone and we thank our long-term shareholders who have supported us in executing our business plan. We believe the added liquidity provided by the public markets allows a broader group of investors to participate in our mission to create new and superior pet medicines that benefit both pets and their owners."

Velcera's proprietary PROMIST drug delivery provides a metered dose liquid mist inside the oral cavity for systemic absorption, which eliminates the need for pets to swallow. By providing a substitution for pill formulations, PROMIST will allow Velcera to develop new and improved pet medicines for easier and more assured administration as well as the potential for improved pharmacokinetics.

Velcera, Inc. became a public company in March 2007 through a merger of privately held Velcera Pharmaceuticals and publicly reporting Denali Sciences, Inc. Concurrent with the merger, Velcera completed a $10 million financing through the private sale of approximately 5.3 million units of common stock and warrants to new and existing investors. Maxim Group, LLC acted as sole placement agent in the offering.

About Velcera, Inc.

Velcera (OTCBB: VLCR) is a specialty pharmaceutical company focused on leveraging its patented PROMIST™ delivery to develop veterinary medicines with superior convenience, compliance, and pharmacokinetic advantages that benefit pets and their owners. PROMIST delivery provides a metered dose liquid mist to the oral mucosa for systemic absorption. The convenience of PROMIST has the potential to increase compliance and improve pet health as owners avoid the challenge of getting pets to swallow pills. Other advantages of PROMIST include improved bioavailability, faster absorption and avoidance of the GI track.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Risks that may affect forward-looking information contained in this press release include, without limitation, the risk that the results of clinical trials may not support our claims and our lack of experience in developing and commercializing pet pharmaceutical products. Additional risks are described in our Current Report on Form SB-2/A filed with the Securities and Exchange Commission on October 18, 2007. We assume no obligation to update these statements, except as required by law.

Contact Information

  • For more information, please contact:

    Velcera, Inc.
    Dennis Steadman
    President and CEO
    Phone: 267-757-3600
    Fax: 267-757-3601
    Email Contact

    The Ruth Group
    Sara Ephraim (investors)
    Phone: 646-536-7002
    Email Contact

    Jason Rando (media)
    Phone: 646-536-7025
    Email Contact